SB17170 Phase 2 Trial in IPF Patients

Exclusion Criteria

• •1. When there is a primary disease showing UIP patterns (rheumatoid arthritis-related interstitial lung disease, connective tissue disease-related interstitial lung disease, etc.) and/or other clinically significant lung abnormalities
• •2. Patients with confirmed acute exacerbation of IPF within 6 months prior to screening and/or during the screening period
• •3. Patients with lower respiratory tract infections requiring antibiotic treatment
• •4. Patients who underwent major surgery within 3 months before screening or have major surgery planned during the clinical trial
• •5. Patients with a history of malignancy or documented evidence of active or suspected malignancy within 5 years prior to screening
• •6. Patients with evidence of active infection
• •7. Patients with the following cardiovascular and cerebrovascular diseases at the time of screening:
• •* Severe hypertension within 3 months
• •* Myocardial infarction or unstable angina within 6 months
• •* History of thrombotic events within 6 months
• •* Diagnosis of heart failure within 6 months
• •8. Patients with pulmonary hypertension
• •9. Patients who are unable to take drugs orally or have a history of major gastrointestinal surgery or pathological findings that may affect the absorption of the investigational product
• •10. Patients with Human Immunodeficiency Virus (HIV) infection or active hepatitis B or C